Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Viridian Therapeutics Inc VRDN

Healthcare Biotechnology
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also... see more

Current News (NDAQ:VRDN)

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Business Wire February 26, 2026

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 8, 2026

Viridian Therapeutics Prepares for Transformational 2026

Business Wire January 6, 2026

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

Business Wire December 22, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 5, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 7, 2025

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Business Wire November 5, 2025

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

Business Wire November 3, 2025

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

Business Wire October 21, 2025
View More News ››

Opinion & Analysis (NDAQ:VRDN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:VRDN)

Viridian Therapeutics: Advancing Innovative Therapies for Th

http://beyondspx.com/2024/08/01/viridian-therapeutics-advancing-innovative-therapies-for-thyroid-eye-disease-and-autoimmune-disorders/
MikeTester - August 1, 2024

head & shoulders formation completed

watching this one for a possible buy order,so glta.
coolfooldumbguy - February 18, 2020

it's a sell today for me

got out for a profit,but should have sold it a week ago,so glta shareholders.
coolfooldumbguy - February 7, 2020

still holding this stock

watching its performance on a daily basis,it's still climbing,so glta shareholders.
coolfooldumbguy - January 28, 2020

shareholders here are lucky

we are going up 50% today on a really bad day for the stock markets,so glta and please remember that timing is everything and you should...
coolfooldumbguy - January 27, 2020

this one seems to be

on a steady upswing,so glta shareholders.
coolfooldumbguy - January 26, 2020
View more Bullboard ››

Allied Critical Metals Inc.

Allied Critical Metals Inc.

Allied Critical Metals (ACM:CSE) is a Canadian-based mining company focused on the expansion and revitalization of its 100 ...
View More »

Podcasts